Compare KMT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | IRON |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | KMT | IRON |
|---|---|---|
| Price | $38.40 | $81.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $31.67 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 1.1M | 513.8K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 17.17 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $2,030,345,000.00 | N/A |
| Revenue This Year | $9.46 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $24.98 | ★ N/A |
| Revenue Growth | ★ 0.36 | N/A |
| 52 Week Low | $17.30 | $30.82 |
| 52 Week High | $36.34 | $99.50 |
| Indicator | KMT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 83.94 | 53.15 |
| Support Level | $33.97 | $75.60 |
| Resistance Level | $35.10 | $81.19 |
| Average True Range (ATR) | 1.17 | 4.00 |
| MACD | 0.19 | 0.83 |
| Stochastic Oscillator | 67.83 | 91.14 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.